MetaStat Inc
OTC:MTST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MetaStat Inc
Tax Provision
MetaStat Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MetaStat Inc
OTC:MTST
|
Tax Provision
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Tax Provision
-$547m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Danaher Corp
NYSE:DHR
|
Tax Provision
-$633m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-8%
|
|
|
Waters Corp
NYSE:WAT
|
Tax Provision
-$112.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Tax Provision
-$142m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-14%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Tax Provision
-$252m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-5%
|
|
MetaStat Inc
Glance View
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. The company is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
See Also
What is MetaStat Inc's Tax Provision?
Tax Provision
0
USD
Based on the financial report for Feb 28, 2018, MetaStat Inc's Tax Provision amounts to 0 USD.
